Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orforglipron in Obstructive Sleep Apnea and Obesity or Overweight
NCT06649045Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2024
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 3, randomised, double-blind trial in obstructive sleep apnea (OSA) and obesity comparing Orforglipron with Placebo (2 arms). Primary endpoint: Apnea-Hypopnea Index at 52 weeks. Started Oct 2024; status: completed.
02
Drugs
orforglipron
03
Conditions
obstructive sleep apnea (OSA)obesity
Beyond the preview
Go deeper on NCT06649045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06649045.